TD Cowen Lowers Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $1,030.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target lowered by TD Cowen from $1,230.00 to $1,030.00 in a report issued on Tuesday morning. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

REGN has been the subject of several other research reports. Citigroup decreased their target price on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. Wolfe Research initiated coverage on Regeneron Pharmaceuticals in a research note on Friday, November 15th. They set an “outperform” rating and a $1,150.00 target price for the company. Morgan Stanley decreased their target price on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. JPMorgan Chase & Co. decreased their target price on Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating for the company in a research note on Thursday, October 24th. Finally, Wells Fargo & Company decreased their target price on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating for the company in a research note on Friday, January 10th. One research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $973.13.

Regeneron Pharmaceuticals Trading Up 0.7 %

Shares of REGN stock opened at $722.07 on Tuesday. The stock has a market cap of $79.35 billion, a price-to-earnings ratio of 17.87, a PEG ratio of 1.60 and a beta of 0.08. The stock has a 50-day moving average of $717.27 and a 200-day moving average of $914.93. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals has a 1-year low of $642.00 and a 1-year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating the consensus estimate of $11.21 by $0.86. The company had revenue of $3.79 billion during the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.88% and a net margin of 33.61%. The business’s quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $11.86 earnings per share. On average, equities research analysts forecast that Regeneron Pharmaceuticals will post 37.75 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.49%. The ex-dividend date of this dividend is Thursday, February 20th.

Institutional Trading of Regeneron Pharmaceuticals

A number of large investors have recently bought and sold shares of REGN. Centaurus Financial Inc. purchased a new stake in Regeneron Pharmaceuticals in the second quarter worth $118,000. Czech National Bank increased its position in Regeneron Pharmaceuticals by 7.0% in the third quarter. Czech National Bank now owns 21,617 shares of the biopharmaceutical company’s stock worth $22,725,000 after buying an additional 1,405 shares during the last quarter. GAMMA Investing LLC increased its position in Regeneron Pharmaceuticals by 32.6% in the third quarter. GAMMA Investing LLC now owns 1,436 shares of the biopharmaceutical company’s stock worth $1,510,000 after buying an additional 353 shares during the last quarter. Miracle Mile Advisors LLC increased its position in Regeneron Pharmaceuticals by 12.6% in the third quarter. Miracle Mile Advisors LLC now owns 2,562 shares of the biopharmaceutical company’s stock worth $2,693,000 after buying an additional 286 shares during the last quarter. Finally, Greenfield Savings Bank grew its position in shares of Regeneron Pharmaceuticals by 28.6% in the third quarter. Greenfield Savings Bank now owns 612 shares of the biopharmaceutical company’s stock valued at $643,000 after purchasing an additional 136 shares in the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.